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Abstract
Patients with poorly controlled insulin-dependent type 1 or type 2 diabetes rarely
present with glycogenic hepatopathy, which is characterized by hepatomegaly and liver
enzyme abnormalities. Glycogenic hepatopathy occurs as a consequence of excessive
accumulation of glycogen in hepatocytes caused by insulin. We report a young male
patient with type 1 diabetes mellitus who developed glycogenic hepatopathy follow-
ing a suicide attempt by insulin overdose via subcutaneous injection. The patient’smed-
ication/nutrition compliance and adherence to insulin were poorly controlled due to
comorbid schizophrenia. Our patient required a large amount of continuous glucose
to maintain euglycemia for persistent intractable hypoglycemia induced by overdose
of long-acting insulin. On admission day 4, the patient presented elevated transami-
nases, hepatomegaly, and lactic acidosis. Computed tomography revealed swollen liver
parenchyma with a diffusely high absorption. The patient gradually recovered without
any medical intervention except for adequate control of blood sugar and was moved
to a psychiatric ward on day 8 for schizophrenia management. This report may help
emergency physicians be aware of the common symptoms, clinical course, and patho-
physiology of glycogenic hepatopathy. Doctors should include glycogenic hepatopathy
in the differential diagnosis of abnormal liver enzymes and hepatomegaly for thosewith
poorly controlled insulin-dependent diabetes mellitus or unstable blood sugar levels
due to insulin overdose like our patient.
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1 INTRODUCTION
Glycogenic hepatopathy is an uncommon complication in patients with
poorly controlled insulin-dependent type 1 or type 2 diabetes. The
pathophysiology of glycogenic hepatopathy is glycogen accumulation
within hepatocytes, leading to hepatic dysfunction with elevated liver
enzymes along with hepatomegaly.1,2 During hyperglycemic periods,
glucose freely infiltrates hepatocytes, activating synthesis of glycogen,
which is further amplified by dosing with insulin to supraphysiologic
levels. Because emergency physicians still under recognize glycogenic
hepatopathy in the clinical setting, differentiating glycogenic hep-
atopathy from non-alcoholic fatty liver disease is important. Here, we
report an uncommon case of glycogenic hepatopathy that occurred in a
patient with poorly controlled type 1 diabetes mellitus who attempted
suicide by injecting himself with long-acting insulin. Due to the sus-
tained release of long-acting insulin in the subcutaneously injected
overdose, prolonged continuous infusion of concentrated glucose was
required, which might have triggered the development of glycogenic
hepatopathy in this patient. Although glycogenic hepatopathy is a rare
condition, emergency physicians should be aware of the condition as
a differential diagnosis for hepatic dysfunction during the follow-up
period of patients with unstable glucose levels treated with insulin.
2 CASE REPORT
A 25-year-old man was brought to our hospital by his family after he
attempted suicide by injecting himself subcutaneously with a massive
insulin dose, estimated quantities of 3600 units of insulin glargine and
2100 units of insulin lispro. The patient was experiencing a cold sweat
and was feeling groggy. Past medical history of the patient included
type 1 diabetes mellitus diagnosed at 11 months old and treated with
insulin for 24 years. He was also diagnosed with comorbid schizophre-
nia at age 23 and had been treatedwith brexpiprazole for 2 years. Four
months prior to admission, the patient fell froman8-meter height, self-
injected an insulin overdose in a suicide attempt, and was hospitalized
F IGURE 1 The sequential record shows the blood sugar concentration and the average of the 8-hour glucose dose. ALT, alanine transaminase;
AST, aspartate aminotransferase (IU/L)
for 3 months. After discharge, the patient discontinued his antipsy-
chotic treatment and continued to suffer from suicidal urges.
The vital signs and physical examination results at his initial visit
were as follows: blood pressure was 136/83 mmHg, pulse was 110
beat/min, respirations were 23/min, temperature was 36.1◦C, and a
blood sugar level of 50 mg/dL. His consciousness level was alert with-
out neurological defects. Cardiovascular and respiratory examinations
were unremarkable. An injection scar was found on his right abdomen.
Psychiatric examination revealed that the patient had auditory halluci-
nation.
Laboratory data were as follows: white blood cells, 15,400/µL;
hemoglobin, 16.1 g/dL; platelet, 270,000/µL; serum albumin, 4.3 g/dL;
aspartate transaminase, 22 IU/L; alanine aminotransferase, 16 IU/L;
total-bilirubin, 0.77 mg/dL; creatinine, 0.59 mg/dL; urea nitrogen,
16.7mg/dL; sodium, 144mmol/L; potassium, 2.6mmol/L; and chlorine,
106 mmol/L. Arterial blood gas analysis on ambient air showed a pH
of 7.4, PaO2, 118.3 mmHg, PaCO2 33.9 mmHg, HCO3
− 22.0 mmol/L,
base excess −3.5 mmol/L, and lactate 3.2 mmol/L. The patient was
admitted to the emergency intensive care unit for careful monitor-
ing and maintenance of blood sugar and electrolytes. The patient
complained of occasional sweating, palpitation due to tachycardia
around 120–140 bpm, and right rib pain. Because the blood sugar
levels were sustained low, the patient required an additional dose of
glucose to maintain euglycemia despite initiation of oral intake and
continuous intravenous injection of a 17.5% solution of glucose infu-
sion via central venous catheter (Figure 1). The first immunoreactive
insulin measurement was 58,525 µU/mL, which gradually decreased
and improved to within a normal range on day 7. The patient was
given about 900 g of glucose/day for the first 4 days. On the day 4 of
admission, the patient complained of general fatigue, persistent right
hypochondralgia, abdominal discomfort, and appetite loss. Follow-
up blood chemistry confirmed elevated transaminases. Aspartate
aminotransferase, alanine transaminase, and lactate were 1441 IU/L,
799 IU/L, and 4.9 mmol/L, respectively. Abdominal ultrasound demon-
strated homogenous enlargement of the liver. A sectional computed
tomography (CT) scan revealed that the liver parenchyma was swollen
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F IGURE 2 A diffuse high absorption area could be confirmed
throughout the liver. The arrow indicates an areameasuring 102
Hounsfield units (HU), which is higher than normal liver parenchyma
(30–60HU)
and showed a diffusely high absorption (Figure 2). The patient did not
undergo a liver biopsy. Based on the clinical episode and because liver
function and systemic symptoms subsequently improved by day 8 in
the hospital, the patient was moved to a psychiatric ward for manage-
ment of schizophrenia. Thereafter, his liver function improved to the
normal range by day 20. Currently, his glycemia is being controlled
by ensuring compliance with insulin therapy and dietician-directed
education.
3 DISCUSSION
The pathological mechanism of glycogenic hepatopathy is accumula-
tion of glycogen in hepatocytes. Insulin and surplus glucose activate
glycogen synthase phosphatase conversion to activated glycogen syn-
thase, which is an enzyme needed for glucose-6-phosphate to convert
to glycogen, which consequently advances the formation of glycogen
and its storage in the liver and obstructs glycogenesis, boosting stores
of hepatic glycogen during hyperglycemia (Tsujimoto, 2006).3 In our
patient, sustained release of self-injected insulin from the tissue of the
injected site might have further driven glycogen synthesis and inhib-
ited gluconeogenesis and glycogenolysis, leading to boosting hepato-
cyte glycogen stores. Glycogen overload leads to hepatomegaly.
The symptoms of glycogenic hepatopathy can include abdominal
pain and obstructive manifestations such as nausea, early satiety, and
vomiting. The usual biochemical results are mildly to moderately high
aminotransferases and alkaline phosphatase elevations. The overall
prognosis of glycogenic hepatopathy is fairwithout progression to liver
fibrosis. The abnormalities, including hepatomegaly and elevated liver
enzymes, are easily reversiblewith continuous euglycemic control. The
othermajor origin of hepatomegaly in diabetic patients is non-alcoholic
fatty liver disease. Non-alcoholic fatty liver disease usually progresses
to liver cirrhosis, whereas glycogenic hepatopathy can be reversed
by maintenance of better glycemic control, and glycogen deposition
does not lead to liver fibrosis.4 Liver biopsy is still considered the most
optimum detection method. Characteristic histological findings are
swollen hepatocytes with intracytoplasmic glycogen accumulation in
hematoxylin and eosin stain and also abundant glycogen highlighted
by periodic acid-Schiff staining.4 On the other hand, noninvasive
imaging modalities such as abdominal ultrasound, magnetic resonance
imaging (MRI), and CT help with diagnosis. Either disease indicates
bright liver by ultrasound of abdomen. Liver CT shows high density
in glycogenic hepatopathy, but low density for non-alcoholic fatty
liver disease.5 MRI typically presents low intensity on T2-weighted
images for glycogenic hepatopathy; furthermore gradient-dual echo
MRI helps distinguish glycogenic hepatopathy fromnon-alcoholic fatty
liver disease, showing differences in appearance between glycogen
deposition and fatty tissue.2,6 Non-alcoholic fatty liver disease might
present low intensity in phase and high intensity out of phase in
gradient-dual echo MRI. In our case, neither liver biopsy nor MRI
imaging was performed; however, elevated hepatic transaminases,
abdominal pain at right hypochondrium to epigastrium with swollen
liver, high liver density on CT, poorly controlled blood sugar, and
excessive use of long-acting insulin led to the diagnosis of glycogenic
hepatopathy.
Poor control of diabetes in schizophrenia may occur due to factors
including physical inactivity and poor diet. The relationship between
type 1 diabetes mellitus and schizophrenia has been controversial.
The prevalence of schizophrenia among patients with type 1 diabetes
mellitus is estimated to be between 0.20% and 1.5%.7 Galler et al8
published that 0.48% of those with type 1 diabetes up to the age of 25
(median age= 17.0) were being treatedwith antipsychotic medication,
and those receiving antipsychotic drugs had poorer glycemic control
and more acute complications compared with those not on antipsy-
chotic drugs. Like the present case, patients with both type 1 diabetes
and schizophrenia are an especially vulnerable group at risk for both
psychological and somatic issues. Many insulin-treated patients are
susceptible to developing hypoglycemia and subsequently visiting
the emergency department, so emergency physicians must treat
hypoglycemia by infusing glucose as a first-line management to avoid
prolonged central nerve system disorder. Hypoglycemia symptoms
include cold sweat, the patient feeling cold due to peripheral circu-
latory disorders, and tachycardia. Our patient was alert with stable
vital signs and did not present these subjective symptoms during the
follow-up period, although eventually his blood glucose levels dropped
lower than 50 mg/dL. Frequent hypoglycemia attenuates the regular
sympathoadrenal reaction and adjusts to low plasma glucose level
concentration; hypoglycemia-associated autonomic failure in diabetes
causes a lack of impaired awareness resulting from this lowering
of the hypoglycemic level threshold.9,10 Physicians might be able
to adjust to a lower dose of glucose while monitoring the patient’s
symptoms.
Insulin self-injection is a good treatment choice for patients
with diabetes due to the potential for incremental improvement of
metabolic control. Insulin lispro, a rapid-acting human insulin analog,
starts to work 15minutes after subcutaneous injection and lasts about
5 hours. On the other hand, insulin glargine is a long-acting insulin,
1100 FUJISAKI ET AL.
lasting over 24 hours with no pronounced peak. Subcutaneous injec-
tion of a massive dose in tissue might provide a depot effect, which
causes a prolonged outcome by delaying insulin absorption due to local
hypoperfusion and mechanical compression. Plasma insulin concen-
tration is supposed to determine the glucose infusion dose, because
insulin release from the tissue is unpredictable.11 Roberge et al12
reported a maximum glucose deposit rate of 10–11 mg/kg/min. In our
case, themaximumdoseof glucoseadministrationwas13.3mg/kg/min.
Thus, combined therapy, such as glucagon administration, octreotide
administration, and surgical excision of the local insulin injection site,
might be able to avoid concentrated glucose infusion.13 Further, there
is the possibility of shortening the treatment duration and conse-
quently possibly stopping glycogenic hepatopathy.
In conclusion, excessive glucose administration for hypoglycemia in
the setting of insulin overdose may lead to glycogenic hepatopathy in
a patient with uncontrolled diabetes. Emergency physicians should be
aware of the common symptoms of glycogenic hepatopathy, such as
hepatomegaly and elevated hepatic transaminases.
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